News

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a ...
Morgan Stanley Slashes Asana (ASAN) Price Target to $13, Keeps Underweight Rating
The rating update came after the company announced fiscal Q1 2026 results on June 3, with revenue reaching $187.3 million, ...
BofA Reiterates Buy Rating on Asana (ASAN), Lowers PT to $21
Bank of America Securities analyst Michael Funk reiterated a Buy rating for Asana, Inc. (NYSE:ASAN), reducing the price ...